(S)-2-(2,3-dihydro-1H-3a,6-diaza-cyclopenta [a]inden-8-yl)-1-methyl-ethylamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: (S)-2-(2,3-dihydro-1H-3a,6-diaza-cyclopenta [a]inden-8-yl)-1-methyl-ethylamine
• 英文别名: (2S)-1-(7,8-dihydro-6H-pyrido[3,4-b]pyrrolizin-5-yl)propan-2-amine
• 化学式: C₁₃H₁₇N₃
• 分子量: 215.298
• InChiKey: HVHVXSNVYIVPKS-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Aza- indolyl derivatives for treating obesity
  申请人：——

  公开号：US20010025039A1

  公开（公告）日：2001-09-27

  Novel compounds of formula (I): 1 wherein X 1 , X 2 , X 3 and X 4 , n, R 1 , R 2 and R 3 are defined in the specification, and pharmaceutically acceptable salts and prodrugs of the compounds of formula (I) have therapeutic uses. These compounds are useful for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea. They are particularly useful for the treatment of obesity.

  式(I)的新化合物：其中X1、X2、X3和X4、n、R1、R2和R3在规范中有定义，化合物的药物可接受的盐和前药具有治疗用途。这些化合物对于治疗中枢神经系统疾病、中枢神经系统损伤、心血管疾病、胃肠道疾病、尿崩症和睡眠呼吸暂停症等疾病有用。它们特别适用于肥胖症的治疗。
• New aza-indolyl derivatives for the treatment of obesity
  申请人：VERNALIS RESEARCH LIMITED

  公开号：EP1132389A1

  公开（公告）日：2001-09-12

  The present invention refers to chemical compounds of formula (I); wherein X1, X2, X3 and X4, n, R1, R2 and R3 and pharmaceutically acceptable salts and prodrugs thereof, and the use thereof in therapy, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and particularly for the treatment of obesity.

  本发明涉及式（I）化合物； 其中X1、X2、X3和X4、n、R1、R2和R3及其药学上可接受的盐和原药，以及它们在治疗中的用途，特别是用于治疗中枢神经系统疾病；中枢神经系统损伤；心血管疾病；胃肠道疾病；糖尿病和睡眠呼吸暂停，尤其是用于治疗肥胖症。
• Treatment of incontinence with 5htc2 agonists
  申请人：Pfizer Inc.

  公开号：EP2277513A2

  公开（公告）日：2011-01-26

  The present invention relates to the use of agonists of 5-HT2C receptors for the treatment of stress urinary incontinence. The present invention also relates to a method of treatment of stress urinary incontinence, to assays to screen for compounds useful in the treatment of stress urinary incontinence, and to methods of preparing compositions for the treatment of stress urinary incontinence.

  本发明涉及使用5-HT2C受体激动剂治疗压力性尿失禁。本发明还涉及一种治疗压力性尿失禁的方法，涉及筛选用于治疗压力性尿失禁的化合物的检测方法，以及涉及制备治疗压力性尿失禁的组合物的方法。
• Treatment of incontinence
  申请人：Pfizer Inc

  公开号：US20040235856A1

  公开（公告）日：2004-11-25

  The present invention relates to the use of agonists of 5-HT2C receptors for the treatment of urinary incontinence, preferably mixed incontinence or stress urinary incontinence. The invention also relates to the use of antagonists of 5-HT2C receptors for the treatment of urine retention. The present invention also relates to a method of treatment of incontinence, to assays to screen for compounds useful in the treatment of incontinence, and to methods of preparing compositions for the treatment of urinary incontinence.

  本发明涉及使用 5-HT2C 受体的激动剂治疗尿失禁，最好是混合性尿失禁或压力性尿失禁。本发明还涉及使用 5-HT2C 受体拮抗剂治疗尿潴留。本发明还涉及一种治疗尿失禁的方法，涉及筛选治疗尿失禁有用化合物的检测方法，以及制备治疗尿失禁组合物的方法。
• NEW AZA-INDOLYL DERIVATIVES
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1274711A1

  公开（公告）日：2003-01-15